Herpes Simplex Epidemiology Forecast

DelveInsight's 'Herpes Simplex - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Herpes Simplex epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Herpes Simplex Understanding

The DelveInsight Herpes Simplex epidemiology report gives a thorough understanding of the Herpes Simplex by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Herpes Simplex in the US, Europe, and Japan. The report covers the detailed information of the Herpes Simplex epidemiology scenario in seven major countries (US, EU5, and Japan).


Herpes Simplex Epidemiology Perspective by DelveInsight

The Herpes Simplex epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Herpes Simplex epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Herpes Simplex epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Herpes Simplex Detailed Epidemiology Segmentation

The Herpes Simplex epidemiology covered in the report provides historical as well as forecasted Herpes Simplex epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Herpes Simplex report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Herpes Simplex report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Herpes Simplex Epidemiology Report and Model provide an overview of the risk factors and global trends of Herpes Simplex in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Herpes Simplex in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Herpes Simplex
  • The report provides the segmentation of the Herpes Simplex epidemiology


Report Highlights

  • 11-Year Forecast of Herpes Simplex epidemiology
  • 7MM Coverage
  • Total Cases of Herpes Simplex
  • Total Cases of Herpes Simplex according to segmentation
  • Diagnosed cases of Herpes Simplex


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Herpes Simplex?
  • What are the key findings pertaining to the Herpes Simplex epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Herpes Simplex across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Herpes Simplex?
  • What are the currently available treatments of Herpes Simplex?


Reasons to buy

  • The Herpes Simplex Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Herpes Simplex market
  • Quantify patient populations in the global Herpes Simplex market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Herpes Simplex therapeutics in each of the markets covered
  • Understand the magnitude of Herpes Simplex population by its epidemiology
  • The Herpes Simplex Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Herpes Simplex

3. Herpes Simplex: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Herpes Simplex Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Herpes Simplex Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Herpes Simplex Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Herpes Simplex Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Herpes Simplex Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Herpes Simplex Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Herpes Simplex Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Herpes Simplex Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Herpes Simplex Treatment and Management

6.2. Herpes Simplex Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Herpes Simplex Epidemiology in 7MM (2017-2030)

Table 2 Herpes Simplex Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Herpes Simplex Epidemiology in the United States (2017-2030)

Table 4 Herpes Simplex Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Herpes Simplex Epidemiology in Germany (2017-2030)

Table 6 Herpes Simplex Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Herpes Simplex Epidemiology in France (2017-2030)

Table 8 Herpes Simplex Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Herpes Simplex Epidemiology in Italy (2017-2030)

Table 10 Herpes Simplex Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Herpes Simplex Epidemiology in Spain (2017-2030)

Table 12 Herpes Simplex Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Herpes Simplex Epidemiology in the United Kingdom (2017-2030)

Table 14 Herpes Simplex Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Herpes Simplex Epidemiology in Japan (2017-2030)

Table 16 Herpes Simplex Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Herpes Simplex Epidemiology in 7MM (2017-2030)

Figure 2 Herpes Simplex Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Herpes Simplex Epidemiology in the United States (2017-2030)

Figure 4 Herpes Simplex Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Herpes Simplex Epidemiology in Germany (2017-2030)

Figure 6 Herpes Simplex Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Herpes Simplex Epidemiology in France (2017-2030)

Figure 8 Herpes Simplex Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Herpes Simplex Epidemiology in Italy (2017-2030)

Figure 10 Herpes Simplex Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Herpes Simplex Epidemiology in Spain (2017-2030)

Figure 12 Herpes Simplex Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Herpes Simplex Epidemiology in the United Kingdom (2017-2030)

Figure 14 Herpes Simplex Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Herpes Simplex Epidemiology in Japan (2017-2030)

Figure 16 Herpes Simplex Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Herpes Simplex Epidemiology
  • Herpes Simplex
  • Herpes Simplex Pipeline
  • Herpes Simplex Companies
  • Herpes Simplex prevalent populatio...
  • Herpes Simplex incident population
  • Herpes Simplex patients diagnosed
  • Herpes Simplex treatment algorithm...

Forward to Friend

Need A Quote